The pathogenesis of drug-induced liver injury

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 10, 2016, Pages 1175-1185

  Lee, Sun Jae ^a   Lee, Youn Ju ^a   Park, Kwan Kyu ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

diagnosis; DILI; histology; liver biopsy; pathogenesis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALLOPURINOL; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARTATE AMINOTRANSFERASE; CHLORPROMAZINE; COTRIMOXAZOLE; CYTOCHROME P450; DIDANOSINE; FLOXURIDINE; IMIPRAMINE; INTERLEUKIN 17; INTERLEUKIN 9; IPILIMUMAB; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; PHENYTOIN; QUINOLONE DERIVATIVE; RANTES; SALICYLIC ACID; STEROID; SULFONAMIDE; TETRACYCLINE; TIABENDAZOLE; UNINDEXED DRUG; VALPROIC ACID; VANCOMYCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; APOPTOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DISEASE MARKER; DRUG RESPONSE; HUMAN; INNATE IMMUNITY; LIVER BIOPSY; PATHOGENESIS; PROGNOSIS; REVIEW; RISK FACTOR; SEROLOGY; TOXIC HEPATITIS;

EID: 84988527723     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1080/17474124.2016.1196133     Document Type: Review

References (109)

1. G.Abboud, N.Kaplowitz Drug-induced liver injury. Drug Saf. 2007;30:277–294.
2. S.S.Bale, L.Vernetti, N.Senutovitch, et al. In vitro platforms for evaluating liver toxicity. Exp Biol Med (Maywood). 2014;239:1180–1191.
3. U.A.Boelsterli, P.L.Lim. Mitochondrial abnormalities–a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol. 2007;220:92–107.
4. D.K.Ingawale, S.K.Mandlik, S.R.Naik. Models of hepatotoxicity and the underlying cellular, biochemical and immunological mechanism(s):a critical discussion. Environ Toxicol Pharmacol. 2014;37:118–133.• A review which focuses and discusses on probable underlying cellular, molecular, immunological, and biochemical mechanisms of hepatotoxicity in vivo animal models and in vitro methods.
5. G.Ostapowicz, R.J.Fontana, F.V.Schiødt, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954.
6. T.Khoury, A.A.Rmeileh, L.Yosha, et al. Drug induced liver injury:review with a focus on genetic factors, tissue diagnosis, and treatment options. J Clin Transl Hepatol. 2015;3:99–108.
7. W.M.Lee. Drug-induced acute liver failure. Clin Liver Dis. 2013;17:575–586, viii.
8. P.B.Watkins. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther. 2011;89:788–790.
9. H.J.Zimmerman. Hepatotoxicity:the adverse effects of drugs and other chemicals on the liver. Philadelphia (PA):Lippincott Williams & Wilkins; 1999.
10. T.Luedde, N.Kaplowitz, R.F.Schwabe. Cell death and cell death responses in liver disease:mechanisms and clinical relevance. Gastroenterology. 2014;147:765–783; e764.
11. C.Stephens, R.J.Andrade, M.I.Lucena. Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol. 2014;14:286–292.• A review which summarizes the current understanding of the molecular mechanism behind idiosyncratic DILI.
12. R.J.Fontana, P.B.Watkins, H.L.Bonkovsky, et al. Drug-induced liver injury network (DILIN) prospective study:rationale, design and conduct. Drug Saf. 2009;32:55–68.
13. H.Takikawa, Y.Murata, N.Horiike, et al. Drug-induced liver injury in Japan:an analysis of 1676 cases between 1997 and 2006. Hepatol Res. 2009;39:427–431.
14. M.Molokhia, P.McKeigue. EUDRAGENE:European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics. 2006;7:633–638.
15. R.J.Andrade, M.I.Lucena, M.C.Fernández, et al. Drug-induced liver injury:an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521.
16. W.Mayoral, J.H.Lewis, H.Zimmerman. Drug-induced liver disease. Curr Opin Gastroenterol. 1999;15:208–216.
17. B.Karczmarek-Borowska, A.Sałek-Zań. Hepatotoxicity of molecular targeted therapy. Contemp Oncol (Pozn). 2015;19:87–92.
18. K.G.Blumenthal, S.U.Patil, A.A.Long. The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Allergy Asthma Proc. 2012;33:165–171.
19. E.Björnsson. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand. 2008;118:281–290.
20. J.G.O’Grady, S.W.Schalm, R.Williams. Acute liver failure:redefining the syndromes. Lancet. 1993;342:273–275.
21. A.L.Mindikoglu, L.S.Magder, A.Regev. Outcome of liver transplantation for drug-induced acute liver failure in the United States:analysis of the united network for organ sharing database. Liver Transpl. 2009;15:719–729.
22. R.M.Green, S.Flamm. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123:1367–1384.
23. J.R.Senior. Monitoring for hepatotoxicity:what is the predictive value of liver “function” tests? Clin Pharmacol Ther. 2009;85:331–334.
24. P.B.Watkins, L.B.Seeff. Drug-induced liver injury:summary of a single topic clinical research conference. Hepatology. 2006;43:618–631.
25. C.Bénichou. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272–276.
26. E.X.Zheng, V.J.Navarro. Liver injury from herbal, dietary, and weight loss supplements:a review. J Clin Transl Hepatol. 2015;3:93–98.•• A review which highlights the hepatotoxic potential of HDS weight loss products and provides an effort to outline a diagnostic approach for DILI.
27. J.H.Lewis. The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol. 2015;13:2173–2189; e2178.• A review which summarize the current guidelines of diagnosing and managing DILI.
28. P.H.Hayashi, R.J.Fontana. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34:134–144.
29. Q.Shi, H.Hong, J.Senior, et al. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol. 2010;4:225–234.•• A review which summarizes the current practice and future perspectives for DILI biomarkers.
30. N.M.Steuerwald, D.M.Foureau, H.J.Norton, et al. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One. 2013;8:e81974.
31. P.J.Starkey Lewis, J.Dear, V.Platt, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011;54:1767–1776.•• A study which provides the evidence for the potential use of miRNAs as biomarkers of human drug-induced liver injury.
32. C.Roderburg, F.Benz, D.Vargas Cardenas, et al. Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int. 2015;35:1172–1184.
33. S.Russmann, G.A.Kullak-Ublick, I.Grattagliano. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem. 2009;16:3041–3053.
34. R.J.Fontana. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146:914–928.
35. U.A.Boelsterli, K.K.Lee. Mechanisms of isoniazid-induced idiosyncratic liver injury:emerging role of mitochondrial stress. J Gastroenterol Hepatol. 2014;29:678–687.
36. D.A.Leigh, P.J.Lusby, R.T.McBurney, et al. Getting harder:cobalt(III)-template synthesis of catenanes and rotaxanes. J Am Chem Soc. 2009;131:3762–3771.
37. L.Saab, J.Peluso, C.D.Muller, et al. Implication of hepatic transporters (MDR1 and MRP2) in inflammation-associated idiosyncratic drug-induced hepatotoxicity investigated by microvolume cytometry. Cytometry A. 2013;83:403–408.
38. J.L.Woodhead, K.Yang, K.L.Brouwer, et al. Mechanistic modeling reveals the critical knowledge gaps in bile acid-mediated DILI. CPT Pharmacometrics Syst Pharmacol. 2014;3:e123.
39. M.A.Welch, K.Kock, T.J.Urban, et al. Toward predicting drug-induced liver injury:parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors. Drug Metab Dispos. 2015;43:725–734.
40. D.H.Adams, C.Ju, S.K.Ramaiah, et al. Mechanisms of immune-mediated liver injury. Toxicol Sci. 2010;115:307–321.
41. J.Uetrecht, D.J.Naisbitt. Idiosyncratic adverse drug reactions:current concepts. Pharmacol Rev. 2013;65:779–808.
42. J.S.Au, V.J.Navarro, S.Rossi. Review article:drug-induced liver injury–its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther. 2011;34:11–20.
43. J.W.Eun, H.J.Bae, Q.Shen, et al. Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model. J Appl Toxicol. 2015;35:152–164.
44. T.B.Knudsen, D.A.Keller, M.Sander, et al. FutureTox II:in vitro data and in silico models for predictive toxicology. Toxicol Sci. 2015;143:256–267.
45. A.S.Kalgutkar, J.R.Soglia. Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol. 2005;1:91–142.
46. R.A.Roth, P.E.Ganey. Intrinsic versus idiosyncratic drug-induced hepatotoxicity–two villains or one? J Pharmacol Exp Ther. 2010;332:692–697.
47. K.Fisher, R.Vuppalanchi, R.Saxena. Drug-induced liver injury. Arch Pathol Lab Med. 2015;139:876–887.
48. J.R.Mitchell, D.J.Jollow, W.Z.Potter, et al. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther. 1973;187:185–194.
49. J.A.Hinson, D.W.Roberts, L.P.James. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 2010;(196):369–405. doi:10.1007/978-3-642-00663-0_12.
50. D.E.Kleiner, N.P.Chalasani, W.M.Lee, et al. Hepatic histological findings in suspected drug-induced liver injury:systematic evaluation and clinical associations. Hepatology. 2014;59:661–670.• A review to provide an overview of the prevalence, classification, and diagnosis of DILI with emphasis on the histologic pattern of injury observed.
51. W.Lewis, E.S.Levine, B.Griniuviene, et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A. 1996;93:3592–3597.
52. E.Björnsson, E.Kalaitzakis, R.Olsson. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;25:1411–1421.
53. J.Uetrecht. Idiosyncratic drug reactions:past, present, and future. Chem Res Toxicol. 2008;21:84–92.
54. B.K.Park, M.Pirmohamed, N.R.Kitteringham. Role of drug disposition in drug hypersensitivity:a chemical, molecular, and clinical perspective. Chem Res Toxicol. 1998;11:969–988.
55. C.Ju, L.R.Pohl. Tolerogenic role of Kupffer cells in immune-mediated adverse drug reactions. Toxicology. 2005;209:109–112.
56. W.J.Pichler. Pharmacological interaction of drugs with antigen-specific immune receptors:the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2:301–305.
57. S.Bhadauria, R.Mishra, R.Kanchan, et al. Isoniazid-induced apoptosis in HepG2 cells:generation of oxidative stress and Bcl-2 down-regulation. Toxicol Mech Methods. 2010;20:242–251.
58. A.Ramachandran, M.Lebofsky, S.A.Weinman, et al. The impact of partial manganese superoxide dismutase (SOD2)-deficiency on mitochondrial oxidant stress, DNA fragmentation and liver injury during acetaminophen hepatotoxicity. Toxicol Appl Pharmacol. 2011;251:226–233.
59. Z.Bibi. Role of cytochrome P450 in drug interactions. Nutr Metab (Lond). 2008;5:27.
60. U.A.Boelsterli, M.R.Redinbo, K.S.Saitta. Multiple NSAID-induced hits injure the small intestine:underlying mechanisms and novel strategies. Toxicol Sci. 2013;131:654–667.
61. T.J.Urban, A.K.Daly, G.P.Aithal. Genetic basis of drug-induced liver injury:present and future. Semin Liver Dis. 2014;34:123–133.
62. T.Matsumoto, M.Ohno, J.Azuma. Future of pharmacogenetics-based therapy for tuberculosis. Pharmacogenomics. 2014;15:601–607.
63. M.Chen, A.Suzuki, J.Borlak, et al. Drug-induced liver injury:interactions between drug properties and host factors. J Hepatol. 2015;63:503–514.
64. G.P.Aithal. Pharmacogenetic testing in idiosyncratic drug-induced liver injury:current role in clinical practice. Liver Int. 2015;35:1801–1808.
65. N.P.Chalasani, P.H.Hayashi, H.L.Bonkovsky, et al. ACG clinical guideline:the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950–966; quiz 967.
66. N.Chalasani, E.Björnsson. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138:2246–2259.
67. E.S.Hurwitz, M.J.Barrett, D.Bregman, et al. Public health service study of Reye’s syndrome and medications. Report of the main study. JAMA. 1987;257:1905–1911.
68. D.Scheffner, S.König, I.Rauterberg-Ruland, et al. Fatal liver failure in 16 children with valproate therapy. Epilepsia. 1988;29:530–542.
69. F.F.Fountain, E.Tolley, C.R.Chrisman, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection:a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005;128:116–123.
70. M.I.Lucena, R.J.Andrade, M.C.Fernández, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity:a prospective series from Spain. Hepatology. 2006;44:850–856.
71. C.Lammert, E.Bjornsson, A.Niklasson, et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51:615–620.
72. M.Chen, J.Borlak, W.Tong. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58:388–396.
73. N.Kaplowitz. Avoiding idiosyncratic DILI:two is better than one. Hepatology. 2013;58:15–17.
74. K.Ikemura, T.Iwamoto, M.Okuda. Altered functions and expressions of drug transporters in liver, kidney and intestine in disorders of local and remote organs:possible role of oxidative stress in the pathogenesis. Expert Opin Drug Metab Toxicol. 2009;5:907–920.
75. R.K.Verbeeck. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64:1147–1161.
76. A.K.Daly, C.P.Day. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44:116–126.
77. J.D.Stewart, R.Horvath, E.Baruffini, et al. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology. 2010;52:1791–1796.
78. M.I.Lucena, M.Molokhia, Y.Shen, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141:338–347.
79. C.Stephens, M.A.Lopez-Nevot, F.Ruiz-Cabello, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013;8:e68111.
80. D.A.Perwitasari, J.Atthobari, B.Wilffert. Pharmacogenetics of isoniazid-induced hepatotoxicity. Drug Metab Rev. 2015;47:222–228.•• A review to clarify the role and the pharmacological mechanism of the genes involved in the isoniazid-induced hepatotoxicity, especially the pharmacological mechanism of some genes involved in the expression of reactive oxygen species (ROS).
81. S.K.Sharma, A.Balamurugan, P.K.Saha, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166:916–919.
82. R.J.Fontana, P.Hayashi, H.L.Bonkovsky, et al. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci. 2013;58:1766–1775.
83. P.B.Watkins. Biomarkers for the diagnosis and management of drug-induced liver injury. Semin Liver Dis. 2009;29:393–399.
84. R.Teschke, C.Frenzel, J.Schulze, et al. Herbal hepatotoxicity:challenges and pitfalls of causality assessment methods. World J Gastroenterol. 2013;19:2864–2882.
85. T.J.Davern, N.Chalasani, R.J.Fontana, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–1672; e1661–e1669.
86. M.García-Cortés, M.I.Lucena, K.Pachkoria, et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008;27:780–789.
87. M.I.Lucena, R.Camargo, R.J.Andrade, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123–130.
88. R.Teschke, C.Frenzel, A.Wolff, et al. Drug induced liver injury:accuracy of diagnosis in published reports. Ann Hepatol. 2014;13:248–255.
89. G.P.Aithal, M.D.Rawlins, C.P.Day. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ. 1999;319:1541.
90. K.G.Ishak, H.J.Zimmerman. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am. 1995;24:759–786.
91. N.Chalasani, R.J.Fontana, H.L.Bonkovsky, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–1934, 1934; e1921–e1924.
92. A.Suzuki, E.M.Brunt, D.E.Kleiner, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931–939.
93. D.E.Kleiner. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29:364–372.
94. E.M.Hennes, M.Zeniya, A.J.Czaja, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.
95. K.Raja, S.N.Thung, M.I.Fiel, et al. Drug-induced steatohepatitis leading to cirrhosis:long-term toxicity of amiodarone use. Semin Liver Dis. 2009;29:423–428.
96. R.Ramachandran, S.Kakar. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62:481–492.
97. M.J.Robinson, A.M.Rywlin. Tetracycline-associated fatty liver in the male. Report of an autopsied case. Am J Dig Dis. 1970;15:857–862.
98. I.Larosche, P.Lettéron, B.Fromenty, et al. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther. 2007;321:526–535.
99. C.P.Bleeker-Rovers, S.W.Kadir, R.Van Leusen, et al. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med. 2000;57:190–193.
100. N.Kaplowitz. Drug-induced liver injury. Clin Infect Dis. 2004;38(Suppl 2):S44–S48.
101. M.P.Holt, L.Cheng, C.Ju. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol. 2008;84:1410–1421.
102. P.V.Krishnan, -Z.-Z.Feng, S.C.Gordon. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements. J Clin Gastroenterol. 2009;43:672–675.
103. M.Narita, E.Oussoultzoglou, M.-P.Chenard, et al. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol. 2012;19:2230–2237.
104. N.O.Vietor, B.J.George. Oxaliplatin-induced hepatocellular injury and ototoxicity:a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent. J Oncol Pharm Pract. 2012;18:355–359.
105. G.Marino, H.J.Zimmerman, J.H.Lewis. Management of drug-induced liver disease. Curr Gastroenterol Rep. 2001;3:38–48.
106. P.G.Aithal, C.P.Day The natural history of histologically proved drug induced liver disease. Gut. 1999;44:731–735.
107. R.Mohi-ud-din, J.H.Lewis. Drug- and chemical-induced cholestasis. Clin Liver Dis. 2004;8:95–132, vii.
108. R.J.Andrade, M.I.Lucena, N.Kaplowitz, et al. Outcome of acute idiosyncratic drug-induced liver injury:long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44:1581–1588.
109. N.T.Ventham, N.A.Kennedy, E.R.Nimmo, et al. Beyond gene discovery in inflammatory bowel disease:the emerging role of epigenetics. Gastroenterology. 2013;145:293–308.